Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any sex.
• People who are willing and able to give written consent to participate.
• People who are reasonably physically functional — able to carry out basic daily activities, even if not fully active (assessed using a standard medical scale called ECOG, scores 0 to 2).
• People diagnosed with multiple myeloma that has come back or stopped responding to treatment, having already received two previous rounds of treatment, and whose myeloma has stopped responding to two specific types of treatment (proteasome inhibitors and immunomodulators).
• People whose kidneys, liver, and heart are working at an adequate level, as measured by specific blood and imaging tests (confirm with trial site for exact values).
• People whose blood oxygen levels are adequate and who have little to no breathing difficulty at rest.
• People with no active graft-versus-host disease (a complication that can occur after certain transplants) at a significant level (Grade 2–4).
• People whose bone marrow is producing enough blood cells, including white blood cells, lymphocytes, red blood cells, and platelets, at levels meeting specific thresholds (confirm with trial site for exact values).

Who may not be able to join:

• People who are pregnant or currently breastfeeding.
• People with a history of, or current, significant neurological conditions such as epilepsy, severe brain injury, dementia, Parkinson's disease, uncontrolled mental illness, psychosis, stroke within the past 3 months, or similar conditions.
• People whose multiple myeloma has spread to the brain or central nervous system, unless that involvement was effectively treated at least 4 weeks before joining (and at least 8 weeks before the CAR-T cell treatment step) — eligibility in this situation would need to be confirmed with the trial site.
• People with significant heart disease or a serious heart event that occurred within the past 12 months.
• People with an active bacterial, viral, or fungal infection requiring treatment, or active or latent hepatitis B, hepatitis C, HIV, HTLV (types 1 or 2), or syphilis.
• People with a history of autoimmune disease that has damaged an organ or required ongoing immune-suppressing medication within the past 24 months.
• People with signs of active lung inflammation (pneumonitis) on a recent chest scan, or a history of certain lung conditions including drug-induced pneumonitis, idiopathic pulmonary fibrosis, or organising pneumonia.
• People with a history of another cancer, unless they have been free of that cancer for at least 24 months (some exceptions apply, such as certain skin cancers, or breast or prostate cancer managed with hormonal therapy — confirm with trial site).
• People who have recently received certain medications, including high-dose steroids, immune-suppressing drugs, chemotherapy, growth factor injections, live vaccines, certain injections into the spinal fluid, or radiation therapy — specific time restrictions apply for each (confirm with trial site for exact timeframes).
• People who have previously received treatment targeting a protein called BCMA.
• People with a known allergy to albumin, DMSO, cyclophosphamide, fludarabine, or tocilizumab.
• People whom the trial doctor considers unsuitable for any other medical reason.

Important: Always verify eligibility with the trial site directly before applying.